Additionally, therapies targeting pro-survival pathways, such as EGFR or ALK inhibitors, and radiation-sensitizers that target the MAPK pathway (e.g., JNK activators), can further enhance the apoptotic response in NSCLC. Here, ALK is linked to non-small cell lung carcinoma.